Barclays analyst Etzer Darout initiates coverage on Abivax (NASDAQ: ABVX) with a Overweight rating and a price target of $142.00.The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE